The recent 5-year pooled analysis including 563 treatment- naïve patients with BRAF V600E/K mutated, unresectable or metastatic melanoma were randomly assigned to receive either D + T or D plus placebo or vemurafenib (V). This evidence concerns the gene BRAF and metastatic melanoma.